Oral dryness and Sjögren's: an update

Subjects

Key Points

  • Discusses the causes and impact of dry mouth.

  • Discusses the management of dry mouth and Sjögren's.

  • Highlights those patients who should be referred to a specialist centre for management

Abstract

Oral dryness is a very common condition presenting to a general dental practitioner or hospital specialist. The most common cause of oral dryness is drug related, however, patients with Sjögren's syndrome, a multisystem autoimmune condition, may present to their dentist rather than their GP complaining of dry mouth and dry eyes. This update article explores the causes of oral dryness and how to manage it. The update on Sjögren's syndrome explains the latest relevant diagnostic criteria, presenting signs, symptoms, investigations and management principles.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4: Labial salivary gland biopsy.
Figure 5: Focal lymphocytic sialadenitis.
Figure 6
Figure 7
Figure 8

References

  1. 1

    Field E A, Fear S, Higham S M et al. Age and medication are significant risk factors for xerostomia in an English population, attending general dental practice. Gerodontology 2001; 18: 21–24.

    Article  Google Scholar 

  2. 2

    Scully C, Felix D H . Oral Medicine — Update for the dental practitioner. Dry mouth and disorders of salivation Br Dent J 2005; 199: 423–427.

    Article  Google Scholar 

  3. 3

    Wolff A, Joshi R K, Ekstrom J et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D 2017; 17: 1–28.

    Article  Google Scholar 

  4. 4

    Villa A, Wolff A, Narayana N et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis 2016; 22: 365–382.

    Article  Google Scholar 

  5. 5

    Villa A, Wolff A, Afraiman D et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. Clin Oral Invest 2015; 19: 1563–1580.

    Article  Google Scholar 

  6. 6

    Aliko A, Wolff A, Dawes C et al. World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 185–206.

    Article  Google Scholar 

  7. 7

    Challacombe S . The Challacombe Scale. Available at www.challacombescale.co.uk (accessed October 2017).

  8. 8

    Chisholm D M, Mason D K . Labial salivary gland biopsy in Sjögren's Syndrome J Clin Pathol 1968; 21: 656–660.

    Article  Google Scholar 

  9. 9

    Delli K, Dijkstra P U, Stell A J . Diagnostic properties of ultrasound of major salivary glands in Sjögren's syndrome: a meta-analysis Oral Dis 2015; 21: 792–800.

    Article  Google Scholar 

  10. 10

    Astorri E, Sutcliffe N, Richards P et al. Ultrasound of the salivary glands is a strong predictor of labial gland biopsy histopathology in patients with sicca symptoms. J Oral Pathol Med 2016; 45: 450–454.

    Article  Google Scholar 

  11. 11

    Jousse-Joulin S, Nowak E, Cornec D et al. Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability RMD Open 2017; 3: e000364.

    Article  Google Scholar 

  12. 12

    Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

    Article  Google Scholar 

  13. 13

    Shiboski S C, Shiboski C H, Criswell L A et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475–487.

    Article  Google Scholar 

  14. 14

    Shiboski C H, Shiboski S C, Seror R et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome; A consensus and data-driven methodology Involving three International patient cohorts. Ann Rheum Dis 2017; 76: 9–16.

    Article  Google Scholar 

  15. 15

    Barone F, Colafrancesco S . Sjögren's syndrome: from pathogenesis to novel therapeutic targets Clin Exp Rheumatol 2016; 34 (Suppl. 98): S58–S62.

    Google Scholar 

  16. 16

    Theander E, Vasaitis L, Baecklund E et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011; 70: 1363–1368.

    Article  Google Scholar 

  17. 17

    Mercadante V, Al Hamad A, Lodi G, Porter S, Fedele S . Interventions for the management of radiotherapy-induced xerostomia and hypo salivation: A systematic review and meta-analysis. Oral Oncol 2017; 66: 64–74.

    Article  Google Scholar 

  18. 18

    Frost P M, Shirlaw P J, Challacombe S J, Fernandes-Naglik L, Walter J D, Ide M . Impact of wearing an intra-oral lubricating device on oral health in dry mouth patients. Oral Dis 2006; 12: 57–62.

    Article  Google Scholar 

  19. 19

    Gottenberg J E, Ravaud P, Puéchal X et al.: Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren's syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249–258.

    Article  Google Scholar 

  20. 20

    Mariette X, Ravaud P, Steinfeld S et al.: Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50: 1270–1276.

    Article  Google Scholar 

  21. 21

    Moutsopoulos N M, Katsifis G E, Angelov N et al.: Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008; 67: 1437–1443.

    Article  Google Scholar 

  22. 22

    Nocturne G, Cornec D, Seror R, Mariette X . Use of Biologics in Sjögren's Syndrome. Rheum Dis Clin North Am 2016; 42: 407–417

    Article  Google Scholar 

  23. 23

    Bowman S J, Everett CC, O'Dwyer J L et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol 2017; 69: 1440–1450.

    Article  Google Scholar 

  24. 24

    Hackett K L, Deane K H O, Strassheim V A et al. Systematic review of non-pharmacological interventions for primary Sjögren's syndrome. Rheumatology 2015; 54: 2025–2032.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to P. J. Shirlaw.

Additional information

Refereed Paper

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shirlaw, P., Khan, A. Oral dryness and Sjögren's: an update. Br Dent J 223, 649–654 (2017). https://doi.org/10.1038/sj.bdj.2017.882

Download citation

Further reading

Search